Latest news with #Haemonetics
Yahoo
3 hours ago
- Business
- Yahoo
HAE Q1 Earnings Call: Revenue Misses Expectations, Margin Expansion and Product Focus Highlighted
Blood products company Haemonetics (NYSE:HAE). fell short of the market's revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $330.6 million. Its non-GAAP EPS of $1.24 per share was 1.6% above analysts' consensus estimates. Is now the time to buy HAE? Find out in our full research report (it's free). Revenue: $330.6 million (3.7% year-on-year decline) Adjusted EPS: $1.24 vs analyst estimates of $1.22 (1.6% beat) Adjusted EPS guidance for the upcoming financial year 2026 is $4.85 at the midpoint, missing analyst estimates by 1.2% Operating Margin: 21.6%, up from 8.7% in the same quarter last year Organic Revenue was flat year on year (10.2% in the same quarter last year) Market Capitalization: $3.35 billion Haemonetics reported first quarter results marked by revenue declines, but management emphasized the impact of its evolving product portfolio and operational changes. CEO Chris Simon attributed performance to strong growth in the Hospital segment, led by technologies such as TEG and VASCADE, and highlighted the successful divestiture of the Whole Blood business. He noted that expanded adoption of next-generation products, particularly in Plasma technology, contributed to margin improvement. Simon also referenced the company's ongoing focus on higher-margin product categories and operational discipline as factors that contributed to the quarter's profitability, stating, 'Our industry-leading NexSys, TEG and VASCADE technologies continue to propel our growth in attractive markets.' Looking forward, Haemonetics' guidance reflects a cautious outlook as the company anticipates ongoing headwinds from portfolio transitions and external market factors. Management expects organic growth to be driven mainly by increased utilization and share gains in Plasma and Hospital technologies, while acknowledging a potential rebound in collection volumes later in the year. CFO James D'Arecca warned that reported revenue is expected to decline due to the completed Whole Blood divestiture and continued impacts from the CSL contract transition, but emphasized that gross margin expansion and disciplined cost management should support profitability. D'Arecca stated, 'We expect adjusted operating margin to improve by 200 to 300 basis points... supported by continued gains in adjusted gross margin.' Management traced the quarter's performance to a mix of product portfolio shifts, margin expansion, and strategic focus on high-growth segments, while also pointing to contract transitions and market-specific headwinds. Hospital segment momentum: Growth was led by Hospital products, including Blood Management Technologies and Interventional Technologies, with double-digit increases in both franchises. The TEG viscoelastic testing platform saw accelerated adoption, particularly with the launch of the HN cartridge, driving new account openings and transitions from older models. Vascular Closure advances: The VASCADE MVP and MVP XL devices in the Interventional Technologies franchise delivered over 25% growth due to new account openings and increased U.S. and Japanese utilization. However, legacy VASCADE products for coronary and peripheral procedures saw slower growth, which management aims to address through focused sales efforts. Plasma technology adoption: Plasma revenue was buoyed by the adoption of next-generation technologies like Persona and Express Plus, resulting in share gains and increased margins. Management highlighted new multi-year agreements with major collectors, which are expected to continue contributing to growth. Portfolio transformation and divestitures: The completed divestiture of the Whole Blood business enabled resource reallocation to higher-growth, higher-margin areas. This shift contributed to the significant improvement in overall operating margins and supported disciplined capital allocation, including share repurchases. Leadership and organizational changes: The promotions of Roy Galvin to Chief Commercial Officer and Frank Chan to Chief Operating Officer were cited as key steps to strengthen commercial execution and operations, particularly in supporting the Hospital business's long-term growth plans. Haemonetics expects near-term revenue to be shaped by portfolio transitions, while focusing on margin gains and product adoption to drive future growth and profitability. Product utilization and share gains: Management anticipates that growth will be led by increased utilization of existing devices, especially in Plasma and Vascular Closure, supported by recent extended contracts with major plasma collectors. New hospital product launches and technology conversions are expected to offset headwinds in legacy product lines. Margin expansion and cost discipline: The company projects further improvement in operating margins through portfolio mix shifts towards higher-margin products and ongoing cost control measures. Approximately $30 million in savings are expected over the next two years through regional alignment and operational efficiencies. External risks and market headwinds: Haemonetics identified tariff exposure, timing of contract transitions, and softness in the Chinese market as areas of uncertainty. While management expects U.S. and European momentum to offset challenges, external factors could impact both revenue progression and profitability in the coming quarters. In the next few quarters, the StockStory team will monitor (1) the pace of technology adoption and utilization in the Plasma and Hospital segments, (2) execution against targeted improvements in Vascular Closure—especially legacy product turnaround efforts, and (3) margin performance as cost savings and portfolio transformation initiatives take hold. Progress on regulatory approvals and new product launches will also be important milestones. Haemonetics currently trades at a forward P/E ratio of 14.2×. Should you double down or take your chips? The answer lies in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-05-2025
- Business
- Yahoo
Haemonetics Corporation Just Beat EPS By 8.7%: Here's What Analysts Think Will Happen Next
Investors in Haemonetics Corporation (NYSE:HAE) had a good week, as its shares rose 6.8% to close at US$68.19 following the release of its annual results. Haemonetics reported US$1.4b in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of US$3.31 beat expectations, being 8.7% higher than what the analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year. Our free stock report includes 1 warning sign investors should be aware of before investing in Haemonetics. Read for free now. Taking into account the latest results, the eight analysts covering Haemonetics provided consensus estimates of US$1.32b revenue in 2026, which would reflect a measurable 3.0% decline over the past 12 months. Statutory earnings per share are predicted to accumulate 9.1% to US$3.64. In the lead-up to this report, the analysts had been modelling revenues of US$1.33b and earnings per share (EPS) of US$3.90 in 2026. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a minor downgrade to their earnings per share forecasts. See our latest analysis for Haemonetics The consensus price target held steady at US$93.30, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Haemonetics at US$120 per share, while the most bearish prices it at US$68.00. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that revenue is expected to reverse, with a forecast 3.0% annualised decline to the end of 2026. That is a notable change from historical growth of 10% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 8.2% per year. It's pretty clear that Haemonetics' revenues are expected to perform substantially worse than the wider industry. The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Haemonetics. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Haemonetics' revenue is expected to perform worse than the wider industry. The consensus price target held steady at US$93.30, with the latest estimates not enough to have an impact on their price targets. With that in mind, we wouldn't be too quick to come to a conclusion on Haemonetics. Long-term earnings power is much more important than next year's profits. We have forecasts for Haemonetics going out to 2028, and you can see them free on our platform here. Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Haemonetics that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
10-05-2025
- Business
- Yahoo
Haemonetics Full Year 2025 Earnings: EPS Beats Expectations
Revenue: US$1.36b (up 4.0% from FY 2024). Net income: US$167.7m (up 43% from FY 2024). Profit margin: 12% (up from 9.0% in FY 2024). EPS: US$3.33 (up from US$2.32 in FY 2024). Our free stock report includes 1 warning sign investors should be aware of before investing in Haemonetics. Read for free now. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 8.7%. Looking ahead, revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Performance of the American Medical Equipment industry. The company's shares are up 6.8% from a week ago. It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Haemonetics, and understanding this should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
09-05-2025
- Business
- Yahoo
Haemonetics Corp (HAE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...
Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Haemonetics Corp (NYSE:HAE) reported solid earnings growth in Q4 2025, with robust margin expansion and strong cash flow. The company achieved a total revenue of $1.4 billion, reflecting 4% growth on a reported basis and 8% organic growth excluding CSL and whole blood divestiture. Haemonetics Corp (NYSE:HAE) executed a $150 million share buyback, reflecting strong conviction in its long-term growth trajectory. The hospital business showed significant growth, with hospital revenue increasing by 12% in the quarter and 24% in fiscal 2025. The company expects continued double-digit revenue growth in vascular closure driven by growth in procedures, share gains, and improved utilization. Plasma revenue declined 9% in the quarter and 6% in fiscal 2025 due to the planned CSL transition. Blood Center revenue declined 22% in the quarter and 8% in fiscal 2025 on a reported basis due to the whole blood divestiture. The company expects plasma revenue to decline 7 to 10% on a reported basis in fiscal 2026. Haemonetics Corp (NYSE:HAE) faces ongoing impacts from pulse field ablation on its esophageal protection business. The company anticipates a decline in blood center revenue by 23 to 26% on a reported basis in fiscal 2026 due to portfolio streamlining. Warning! GuruFocus has detected 2 Warning Sign with HAE. Q: Hi, thanks for taking the question and congrats on a good quarter. I wanted to start with plasma. You had a nice beat in the quarter and the guide for fiscal '26 came in at 11 to 14%, excluding CSL, which was ahead of expectations. Can you talk more about what you're seeing in the collections environment and what's assumed in guidance between pricing, share gains, and volumes? A: Morning, Rohan. It's Chris. We remain very bullish on plasma, near and longer term. The underlying demand for IG remains robust. The 11 to 14% growth is almost entirely share gains and a premium associated with our upgraded technology adoption. We don't see meaningful growth in the first half of fiscal '26 in terms of collection volume, but we believe that will change in the second half of the year. Q: Can you elaborate more on the EPS guidance of $4.70 to $5 in fiscal '26, which includes a 26 to 27% operating margin? What are the drivers here from a gross margin and OpEx standpoint? A: Hi, Rohan, it's James Dereka. We see continued improvement in gross margin mix driving the operating margin of 26 to 27%. As we rationalize the portfolio, gross margins have continued to improve. Regarding tariffs, we've built in an annualized impact of $0.20 at the midpoint of our range, and we have the ability to continue mitigating tariffs as we move forward. Q: Hi, thanks for taking the questions. Wanted to drill down more on the vascular closure portfolio. You reported nice growth from newer products like MVP and XL. What are you seeing in terms of share gains and new account penetration with these products? A: Thanks, Marie, it's Chris. We published supplemental tables to clarify the opportunity set and total addressable market. For FY '26, we're looking at high single-digit growth in the US. We're impressed by the team's results with MVP and MVP XL, but we need to address the drag from coronary and peripheral. We've targeted our US field force to focus on vascular closure and structural heart, which is producing interesting new growth opportunities. Q: Can you talk about any changes to strategy following the management change in the hospital segment? Also, can you give an idea of the margin expansion seen in this segment? A: Thanks, Marie. The hospital segment is a big contributor to margin expansion. We're playing and winning in collections, which is an important source of baseline growth. The gross margin of the hospital business is in excess of 70%, with operating income in the high 20s. Roy Galvin brings a skill set to help franchise presidents take their business to the next level, and we're excited about the opportunity in front of us. Q: Just looking at where you guided for '26 from an organic perspective, does that imply you'll be at the lower end of the mid to high single-digit growth target post-fiscal '26? A: Mike, we'll issue a new LRP later this year. We've grown this business 10% organically over the four-year period of this LRP. We expect to replicate that performance going forward, knowing we're doing it off a much larger and more profitable base. We play in winning markets with leading products, and we're targeting top quartile medtech categories that support high single-digit or better growth rates. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
07-05-2025
- Business
- Yahoo
Haemonetics (HAE) To Report Earnings Tomorrow: Here Is What To Expect
Blood products company Haemonetics (NYSE:HAE). will be reporting results tomorrow before market open. Here's what you need to know. Haemonetics missed analysts' revenue expectations by 1.3% last quarter, reporting revenues of $348.5 million, up 3.7% year on year. It was a slower quarter for the company, with organic revenue in line with analysts' estimates. Is Haemonetics a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Haemonetics's revenue to decline 4.7% year on year to $327.3 million, a reversal from the 12.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.22 per share. Haemonetics Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Haemonetics has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 2.7% on average. Looking at Haemonetics's peers in the medical devices & supplies - specialty segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Inspire Medical Systems delivered year-on-year revenue growth of 22.7%, beating analysts' expectations by 3.1%, and Integer Holdings reported revenues up 7.3%, topping estimates by 2%. Inspire Medical Systems traded up 1.8% following the results while Integer Holdings was also up 2.6%. Read our full analysis of Inspire Medical Systems's results here and Integer Holdings's results here. There has been positive sentiment among investors in the medical devices & supplies - specialty segment, with share prices up 5.9% on average over the last month. Haemonetics is up 13.5% during the same time and is heading into earnings with an average analyst price target of $96.30 (compared to the current share price of $63.58). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
